News | July 21, 2022
DS-7300 Phase 2 Trial Initiated in Patients with Pretreated ExtensiveStage Small Cell Lung Cancer
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
The company now exceeds the sector benchmark for its overall ESG rating and for all three measures
Strand Life Sciences has sequenced a total of 12800 samples from July, 2021 to June, 2022, and identified more than a 100 lineages circulating in Bengaluru
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
George Svokos joins Avet after serving as a strategic business advisor to numerous global healthcare companies
The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
Orion to receive an upfront payment of USD 290 million
Advancing to IND-enabling studies with multiple drug candidates
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
